tbuckley/cabot-search huggingface dataset:
FRI0335 Earlier onset and brainstem involvement as key features in a brazilian neuro-behÇet's disease cohort
Authors: LL Prado, G Tinone, D Callegaro, CGS Saad, M Levy-Neto, C Goncalves
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Behçet9s disease (BD) is a multisystem disease in which central nervous system involvement – neuro-Behçet9s disease (NBD) – may strike young patients with devastating consequences. In this regard, early diagnosis and treatment is essential to prevent injury. <h3>Objectives</h3> This study aimed to analyze NBD clinical features compared to non-neurological BD in order to distinguish disease patterns. <h3>Methods</h3> A retrospective study was performed in 101 BD outpatients from a single tertiary center followed between 2011 and 2016. BD diagnosis was based on the 2014 International Criteria for Behçet9s Disease. Demographic, clinical and imaging features of 28 NBD patients were compared to 73 BD patients without neurological involvement. <h3>Results</h3> Earlier disease onset was found in NBD compared to BD (26.0±10.2 vs. 30.2±8.8 years, p=0.04). There were no differences between genders incidences, with a female predominance in both groups (64.3 vs. 72.6%, p&gt;0.05). Over half of patients (53.6%) presented NBD as the first symptom and the mean time between diagnosis and NBD onset was 3.8±5.9 years. Uveitis was less frequent in NBD patients (25% vs. 47.9%, p=0.04), together with cutaneous disease (50% vs. 76.7%, p=0.01) and articular involvement (17.9% vs. 46.5%, p=0.01). Oral ulcers, genital ulcers, intestinal and vascular involvement frequencies were similar in both groups. Regarding NBD presentation, brainstem involvement was the most prevalent (67.9%), followed by central venous thrombosis (32.1%), aseptic meningitis (17.9%), stroke (3.6%) and peripheral neuropathy (3.6%). Most patients (82.1%) had a single neurological attack whereas relapsing disease was found in 18.5%. <h3>Conclusions</h3> Our study found an earlier disease onset in NBD patients and a lower frequency of ocular, cutaneous and articular involvement. Moreover, several patients may unfold the disease as NBD, with lack of other manifestations. In addition, brainstem lesions occurred in most patients. Recognizing these disease patterns might support to expedite NBD diagnosis. <h3>Disclosure of Interest</h3> None declared
OP0138-HPR Do patients' treatment beliefs affect treatment choices in knee and hip osteoarthritis?
Authors: EM Selten, R Geenen, HJ Schers, FH van den Hoogen, RG der Meulen-Dilling van, WH van der Laan, MW Nijhof, CH van den Ende, JE Vriezekolk
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Patients9 beliefs about treatment modalities for knee/hip osteoarthritis (OA) might influence their treatment choices. The Theory of Planned Behavior predicts that patients9 beliefs, the norms and values of one9s social environment (subjective norm) and one9s perceived self-efficacy influence behaviour<sup>1</sup>. Moreover, symptom severity may influence treatment choices<sup>2</sup>. However, these relationships have not been studied yet in the context of treatment decision-making. <h3>Objectives</h3> To test whether treatment beliefs, subjective norm, perceived self-efficacy and symptom severity were associated with intended treatment choices in OA. <h3>Methods</h3> Patients with knee/hip OA who visited the Sint Maartenskliniek in 2015 and 2016 (N=700) were invited to fill out a booklet. The Treatment beliefs in OsteoArthritis questionnaire was used to assess positive and negative treatment beliefs regarding five treatment modalities: physical activities, pain medication, physiotherapy, injections and arthroplasty. Other measures were demographic and clinical variables, self-efficacy (ASES), and symptom severity (WOMAC). Associations between variables were assessed in three models (Figure 1): 1) whether treatment beliefs are associated with intended treatment choice (model 1); 2) whether treatment beliefs, subjective norm and perceived self-efficacy are associated with intended treatment choice (model 2); 3) whether treatment beliefs, subjective norm, perceived self-efficacy and symptom severity are associated with intended treatment choice (model 3). Path analyses were conducted to examine the hypothesized associations. <h3>Results</h3> 289 patients filled out the booklet. Model 2 had the highest explained variance for each of the treatment modalities (range 32–45%). Positive treatment beliefs and subjective norm were consistently associated with intended treatment choice across all treatment modalities. Negative treatment beliefs were associated with intended treatment choices for pain medication and arthroplasty. Perceived symptom severity was not related to intended treatment choices. No other associations were found. <h3>Conclusions</h3> This is the first study that found empirical support for the relationship between treatment beliefs and treatment choices. The findings suggest that positive beliefs about treatment modalities and the norms and values of one9s social environment are related to a specific treatment choice for knee/hip OA and should be addressed in the clinician9s consulting room. <h3>References</h3> Ajzen, I. (1991). The Theory of Planned Behavior. Organ Behav Hum Dec 50. 179–211. Rosemann (2007). Health service utilization patterns of primary care patients with osteoarthritis. BMC Health Serv Res 7: 167. <h3>Disclosure of Interest</h3> None declared
Abstract 19969: Combined Non-invasive Coronary Angiography and Myocardial Perfusion Imaging Using 320 Row Detector Computed Tomography: CT Perfusion Acquisition, Reconstruction, and Analysis Methods of the CORE-320 Multi-center Cohort Study
Authors: Richard T George, Armin Arbab-Zadeh, Rodrigo J Cerci, Andrea L Vavere, Kakuya Kitagawa, Marc Dewey, Carlos E Rochitte, Andrew Arai, Narinder Paul, Frank J Rybicki, Albert C Lardo, Joao A Lima
Journal: Circulation (2010)
THU0671 Can an inner disposable glove be used under an electrogoniometric glove for measuring finger movement without loss of accuracy?
Authors: J Connolly, P Gardiner, J Condell, K Curran, D Small
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Improving joint mobility is an important outcome for patients with arthritis, but finger joint range of motion is rarely measured in clinic. Electronic gloves with movement sensors have been developed to measure joint movement accurately and it is now possible to assess dynamic mobility of the finger joints. However these gloves are expensive and it is likely that when carrying out measurements in the patient population they would be used with inner disposable gloves to avoid nonsocomical infection. Establishing accuracy and usability of electronic gloves whilst wearing disposable inner gloves is therefore an important pre-requisite for studies in patients with arthritis. <h3>Objectives</h3> To establish the accuracy and repeatability of measurements of finger movement obtained using two different electrogoniometric gloves worn with and without an inner disposable glove. <h3>Methods</h3> We used two different types of electrogoniometric glove for the purpose of this study. One is the commercially available 5DT dataglove 14 Ultra (5DT, 2011) and the other was produced to our specifications by Tyndall National Institute, University College Cork. We called this the "IMU glove". We developed a graphical interface for both devices to facilitate detailed evaluation of joint movement in each finger. Both gloves were tested using a protocol adapted from Dipietro, Sabatini, &amp; Dario, (2003). <h3>Results</h3> Table 1 displays comparison of Coefficient of Variation (CV) readings for both data gloves. Figure shows this information graphically. Results show no significant change for 5DT angular readings with and without a surgical glove worn underneath the data glove. Results for PIP sensors show an improvement in repeatability with a surgical glove. CV variance was smaller for MCP sensors with a surgical glove worn underneath the data glove compared with no surgical glove. CV for the IMU data glove show negligible changes in MCP readings when a surgical glove is worn underneath. PIP readings show small changes when using a surgical glove. <h3>Conclusions</h3> Inner disposable gloves can be worn when using electrogoniometric gloves for testing finger movement without loss of accuracy or any significant discomfort in patients with arthritis. <h3>References</h3> 5DT, 2011. 5DT Data Glove 14 Ultra [WWW Document]. URL http://www.5dt.com/products/pdataglove14.html(accessed 1.10.12). Dipietro, L., Sabatini, A.M., Dario, P., 2003. Evaluation of an instrumented glove for hand-movement acquisition. J. Rehabil. Res. Dev. 40, 179–89. <h3>Disclosure of Interest</h3> None declared
THU0051 Association between bioactive tnf and eular response to tnf inhibitors in rheumatoid arthritis
Authors: J Poudroux, H Marotte, J-E Gottenberg, S Paul
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> ROC study provided data to manage rheumatoid arthritis (RA) treatment after a failure to a first TNF blocker (1). We previously reported that high circulating TNF bioactivity was associated with good clinical response (2). <h3>Objectives</h3> To explore ability of TNF bioactivity to predict response to second TNF blocker. <h3>Methods</h3> Here, we assessed TNF bioactivity in 130 RA patients from the group rotation to a second TNF blocker at the time of randomisation and after 6 months. Clinical and biological data were recorded at baseline and 6 month with Eular response assessed at 6 month. TNF bioactivity was assessed with HEK-Dual TNF cells adapted from our previous work (2). Due to non-normalised distribution, non parametrical analysis were performed. <h3>Results</h3> Baseline circulating TNF bioactivity was similar according to Eular response. However, circulating TNF bioactivity at 6 month was associated with clinical response with low TNF bioactivity in responders. A ROC analysis suggested a cut-off at 0.320 with a sensitivity at 92% and a specificity at 41%. <h3>Conclusions</h3> After a failure of a first TNF blocker, circulating TNF bioactivity is not able to predict response to a second TNF blocker despite a lower level in responders compared to non-responders. <h3>References</h3> Gottenberg J-E, Brocq O, Perdriger A, Lassoued S, Berthelot J-M, Wendling D, et al. Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. JAMA. 2016 Sep 20;316(11):1172–80. Marotte H, Maslinski W, Miossec P. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther. 2005;7(1):R149–155. <h3>Disclosure of Interest</h3> None declared
AB0840 Local fracture liaison service (FLS): characteristics and first 6 months of evolution in patients after hip fracture: preliminary results
Authors: J Rosas, C Cano, M Lorente, A Pons, E Salas, T Llinares, M Hernández, JM Senabre-Gallego, M Marco-Mingot, JD Alvarado, G Santos-Soler, H Arcos, A García, JI Hernández, JJ Jiménez, X Barber, C Lόpez, MD Lόpez, AM Molinos, B Statti, M Sanchís-Selfa
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Hip fracture has great impact on morbi-mortality, but a large percentage of patients do not receive treatment. <h3>Objectives</h3> To know the characteristics of patients whith hip fracture and its evolution in the first 6 months. <h3>Methods</h3> A prospective, 6-month follow-up study of patients over 60 years old admitted for hip fracture, evaluated in a local FLS. At 3 months after discharge, patients are evaluated for: epidemiological data, fracture income (days of admission, prior and discharge of osteoporosis (OP) drugs, general biochemistry and vitamin D), OP records and possible diseases or osteopenizing drugs, lumbar spine and hip Bone densitometry (BMD) lateral dorsal and lumbar spine radiology and the treatment was decided. The electronic history before and after 6 months of the fracture were reviewed. <h3>Results</h3> Of 152 patients &gt;60 years old, admitted in 2016 due hip fracture, 77 (51%) were during the first 6 months. However, radiology or BMD data were not available for 30 (39%) patients, 16 (21%) for death and 14 (18%) for loss of follow-up. Mean BMI was 26.02±6.2. The mean age of menopause was 49±5 years. 1% of the patients received corticosteroids and 2% of patients an osteopenizing disease (COPD) was found. Mean time of admission was 7.57±2.51 days. In 3% of the patients, before the fracture were receiving OP treatment, which continued to discharge. The mean level of calcium, phosphorus and alkaline phosphatase was normal. However, the mean level of 25OH vitamin D was 13.55±8.63 ng/ml (median: 12 ng/ml, range: &lt;4 to 29 ng/ml). In 11 of the 27 (41%) patients, in whom radiology was available, the presence of vertebral fracture was demonstrated. The mean T-score for lumbar BMD was 1.8±1.65 DE (32%: the result was normal, 36% osteopenia, 32% OP), femoral neck 2.59±0.77 DE (27%: osteopenia, 77% OP) and in total hip: 2.56±0.86 DE (56%:osteopenia and 44% OPand In Ward of 3.2 DE. 100% of patients evaluated in Rheumatology, initiated treatment for OP: zoledronate: 40%, alendronate: 20%, denosumab: 25%, PTH: 15%. <h3>Conclusions</h3> In patients with hip fracture: 1) Mortality is high (21%), in the first 6 months after fracture. 2) The prevalence of vertebral fracture is 40%. 3) It is accompanied by very low blood levels of vitamin D. 4) In a high percentage the result of BMD is normal or osteopenia. 5) A minimum number of patients receive specific treatment for osteoporosis after fracture. 6) Evaluation in a FLS, ensures the evaluation and treatment of patients. <h3>Acknowledgements</h3> The study was supported by a research grant from the Asociaciόn para la Investigaciόn en Reumatología de la Marina Baixa (AIREMB). <h3>Disclosure of Interest</h3> None declared
A Dose Escalation Study of RP6530, a Novel Dual PI3K δ/γ Inhibitor, in Patients with Relapsed/Refractory T-Cell Lymphoma
Authors: Yasuhiro Oki, Auris Huen, Prajak J Barde, Kumar Penmetsa, Alda Ashu, Little Pullokaran, Carol Wilson, Srikant Viswanadha, Madeleine Duvic
Journal: Blood (2016)
AB0145 Tlr4 signaling pathway mediates the senescence of bone marrow- mesenchymal stem cells from systemic lupus erythematosus patients
Authors: J Ji, Y Wu, X Kong, Z Zhang, Z Gu
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Previous studies of our research group revealed the senescence of bone marrow-mesenchymal stem cells from systemic lupus erythematosus patients,which participated in the development of SLE. "Inflammatory microenvironment" played a very important role in cellular senescence. In the preliminary experiments, we discovered the level of HMGB1 in serum and Peripheral blood mononuclear cells from SLE patients was higher than those of The healthy control group. <h3>Objectives</h3> The aim of this study was to investigate whether HMGB-1 can lead to senescence BM-MSCs from SLE patients and its possible mechanism. <h3>Methods</h3> Tewelve female SLE patients and healthy subjects were enrolled in the study. All patients were females, and their age distribution was similar to that of the cases. All BM-MSCs were Isolated by density gradient centrifugation. Western Blotting and immunofluorescence were used to distinguish the difference of expression and localization of TLR4 signaling pathway between normal group and SLE group. Different concentrations (0.01,0.1,1,10ug/ml) of HMGB-1 (the endogenous ligand of TLR4) stimulated normal BM-MSCs, then detecting expression of TLR4 signal by WB, observing the activity of β-gal of cells, the changes of cytoskeletal structure by F-actin staining and the distribution of cell cycle by flow cytometry. We used small interfering RNA (siRNA) to interfere the expression of TLR4. <h3>Results</h3> BM-MSCs from SLE patients showed prominent features of senescence, characterized by impaired capacities of proliferation, increased SA-β-gal activity, and disordered cytoskeleton distribution, and abnormal activation of TLR4 signaling transduction, high level of phosphorylated p65. IκBα. After stimulation of HMGB1 in normal MSCs,TLR4 signaling was activated. And, the cell volume and the number of SA-β-gal positive in SLE BM-MSCs was increased. The organization of cytoskeleton was neatly disordered. The rate of cell proliferation was decreased. The inhibitors of HMGB-1 and small interfering RNA (siRNA) of TLR4 can significantly reverse the senescence. <h3>Conclusions</h3> HMGB-1 binded to TLR4, and by activating MyD88/IRAK/TRAF pathway, promoted NF-κB signal transduction, thereby affected the expression of cell cycle-related proteins, and then resulted in senescence of MSCs from SLE patients. <h3>Acknowledgements</h3> This research was supported by grants from the National Natural Science Foundation of China (81471603). <h3>Disclosure of Interest</h3> None declared
AB0071 Analysis of synovial expression of parvovirus B19 assessed immunohistochemically and correlated to synovitis score
Authors: M Tarasovs, A Kadisa, A Mihailova, S Skuja, M Murovska, V Groma
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Apart from systemic symptoms of viral infection parvovirus B19 (B19) could lead to acute and chronic arthropathy. It has been found in synovial tissue of rheumatoid arthritis (RA) patients, sometimes, being associated with some forms of undifferentiated arthritis. Possibly, it could promote inflammation in various forms of arthritis. <h3>Objectives</h3> To determine the expression of B19 antigens in different compartments of synovial membrane; correlate these findings to the estimated synovitis score. <h3>Methods</h3> 7 RA and 54 osteoarthritis (OA) patients were enrolled in this study. nPCR was used to detect the presence of B19 genomic sequence in 61 samples of synovial tissue. PCR B19 positive tissue samples were immunohistochemically treated with the anti-B19 antibodies detecting B19 capsid proteins9 VP1/VP2 expression estimated thereafter semiquantitatively. The intimal and subintimal layers of synovium as well as vasculature were estimated. Synovial inflammation was evaluated using synovitis score. <h3>Results</h3> 3 RA and 3 OA patients were PCR B19 tissue positive. B19 antigens9 expression was observed in synovial lining, immune infiltrates and vascular endothelium. Correlation between B19 expression observed in synovial cells and inflammatory infiltrates9 lymphocytes and macrophages was r=0.555 (p&lt;0.0001) and r=0.793 (p&lt;0.0001), respectively. Likewise, correlation between vascular endothelial B19 expression and synovial lymphocytic infiltrates was demonstrated r=0.616 (p&lt;0.0001). Determined synovitis score varied from low up to intermediate revealing median value 2. Simultaneously, there was no correlation found between the synovitis score and B19 antigens9 expression. <h3>Conclusions</h3> B19 capsid proteins9 VP1/VP2 expression is detectable in different structural constituents of synovial membrane. Under conditions studied, the tissue expression of B19 antigens does not correlate with the inflammatory indices scored. <h3>Disclosure of Interest</h3> None declared
SAT0376 ANTI-NT5C1A autoantibodies are frequent in juvenile myositis and associated with increased illness severity
Authors: R Yeker, I Pinal-Fernandez, T Kishi, IN Targoff, FW Miller, LG Rider, A Mammen
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Autoantibodies (Abs) against 59-Nucleotidase, Cytosolic 1A (NT5C1A) have been portrayed as a potential diagnostic aide in distinguishing inclusion body myositis (IBM) and polymyositis (PM) in adults. However, 4–21% of dermatomyositis (DM) patients also have Abs to NT5C1A. <h3>Objectives</h3> The prevalence and clinical features of anti-NT5C1A Abs in juvenile-onset myositis (IIM) patients is unknown, so we sought to examine this in a large cohort. <h3>Methods</h3> We screened 384 juvenile IIM patients meeting probable or definite Bohan and Peter criteria for anti-NT5C1A Abs by immunoblotting for the full length NT5C1A protein in transfected and non-transfected lysates. Clinical characteristics and HLA typing were compared between juvenile IIM patients who were anti-NT5C1A positive (Ab+) and those who were anti-NT5C1A negative (Ab-). <h3>Results</h3> In this cohort, 29% (103) of juvenile DM, 15% (3) of juvenile PM, and 37% (15) of juvenile overlap myositis patients tested positive for anti-NT5C1A Abs. Compared with anti-NT5C1A Ab- patients, anti-NT5C1A Ab+ juvenile IIM patients showed a similar distribution of race, gender, and association with myositis-specific Abs. However, NT5C1A Ab was associated with anti-p155/140 Abs (p=0.05). The only observed clinical difference was an increased frequency of V- or shawl-sign rashes ever present (44% vs. 26%, p=0.002). Disease severity was increased in anti-NT5C1A Ab+ patients, based on more frequent hospitalizations (p=0.02), more medications used (p&lt;0.001), and more treatment trials per year (p&lt;0.001). Additionally, pulse steroids (p&lt;0.001) and intravenous immunoglobulin therapy (p=0.008) were prescribed more frequently in anti-NT5C1A Ab+ than Ab- patients. The HLA alleles DRB1*07 (20% vs. 9%, p&lt;0.05) and DQA1*0201 (21% vs. 7%, p&lt;0.01) were present more frequently in anti-NT5C1A Ab- compared to Ab+ patients. <h3>Conclusions</h3> Anti-NT5C1A Abs are commonly present in juvenile DM and juvenile overlap myositis patients, and are present more frequently in patients with anti-p155/140 Abs, but are also seen in association with other myositis specific Abs. Consistent with data in adult IIM patients, anti-NT5C1A Abs have few distinguishing clinical features in juvenile myositis, but are associated with increased illness severity marked by increased hospitalizations and receipt of additional therapy. <h3>Disclosure of Interest</h3> R. Yeker: None declared, I. Pinal-Fernandez Grant/research support from: The Myositis Association, T. Kishi Grant/research support from: The Myositis Association, I. Targoff Consultant for: Oklahoma Medical Research Foundation Clinical Immunology Laboratory regarding myositis autoantibody testing, F. Miller: None declared, L. Rider: None declared, A. Mammen: None declared
Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis
Authors: Axel Petzold, Laura J Balcer, Peter A Calabresi, Fiona Costello, Teresa C Frohman, Elliot M Frohman, Elena H Martinez-Lapiscina, Ari J Green, Randy Kardon, Olivier Outteryck, Friedemann Paul, Sven Schippling, Patrik Vermersch, Pablo Villoslada, Lisanne J Balk, Orhan Aktas, Philipp Albrecht, Jane Ashworth, Nasrin Asgari, Laura Balcer, Lisanne Balk, Graeme Black, Daniel Boehringer, Raed Behbehani, Leslie Benson, Robert Bermel, Jacqueline Bernard, Alexander Brandt, Jodie Burton, Peter Calabresi, Jonathan Calkwood, Christian Cordano, Fiona Costello, Ardith Courtney, Andrés Cruz-Herranz, Ricarda Diem, Avril Daly, Helene Dollfus, Christina Fasser, Carsten Finke, Jette Frederiksen, Elliot Frohman, Teresa Frohman, Elenaw Garcia-Martin, Inés González Suárez, Gorm Pihl-Jensen, Jennifer Graves, Ari Green, Joachim Havla, Bernhard Hemmer, Su-Chun Huang, Jaime Imitola, Hong Jiang, David Keegan, Eric Kildebeck, Alexander Klistorner, Benjamin Knier, Scott Kolbe, Thomas Korn, Bart LeRoy, Letizia Leocani, Dorothee Leroux, Netta Levin, Petra Liskova, Birgit Lorenz, Jana Lizrova Preiningerova, Elena Hernández Martínez-Lapiscina, Janine Mikolajczak, Xavier Montalban, Mark Morrow, Rachel Nolan, Timm Oberwahrenbrock, Frederike Cosima Oertel, Celia Oreja-Guevara, Benjamin Osborne, Olivier Outteryck, Athina Papadopoulou, Friedemann Paul, Axel Petzold, Marius Ringelstein, Shiv Saidha, Bernardo Sanchez-Dalmau, Jaume Sastre-Garriga, Sven Schippling, Robert Shin, Neil Shuey, Kerstin Soelberg, Ahmed Toosy, Rubén Torres, Angela Vidal-Jordana, Pablo Villoslada, Amy Waldman, Owen White, Ann Yeh, Sui Wong, Hanna Zimmermann
Journal: The Lancet Neurology (2017)